Literature DB >> 29350324

Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment.

Ayman Samman Tahhan1, Muthiah Vaduganathan2, Stephen J Greene3, Maureen Okafor4, Sonali Kumar4, Javed Butler5.   

Abstract

PURPOSE OF REVIEW: Clinical trial design and execution are evolving as increasingly important considerations with respect to the success of heart failure trials. The current review highlights temporal trends in characteristics of heart failure clinical trials. RECENT
FINDINGS: Recent trials in heart failure have required longer recruitment phases, displayed inefficient enrollment rates, increased use of composite and nonfatal endpoints, undergone rapid globalization, and gradually increased focus on heart failure with preserved ejection fraction. Understanding patterns and trends in clinical trial design and execution may inform future planning and conduct of trials of heart failure therapeutics.

Entities:  

Keywords:  Clinical trials; Endpoints; Enrollment; Heart failure; Temporal trends

Mesh:

Year:  2018        PMID: 29350324     DOI: 10.1007/s11897-018-0374-z

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  44 in total

1.  Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials.

Authors:  Mohit Bhandari; Jason W Busse; Dianne Jackowski; Victor M Montori; Holger Schünemann; Sheila Sprague; Derek Mears; Emil H Schemitsch; Dianne Heels-Ansdell; P J Devereaux
Journal:  CMAJ       Date:  2004-02-17       Impact factor: 8.262

2.  Clinical trials: the challenge of recruitment and retention of participants.

Authors:  Raisa B Gul; Parveen A Ali
Journal:  J Clin Nurs       Date:  2010-01       Impact factor: 3.036

3.  Effect of nesiritide in patients with acute decompensated heart failure.

Authors:  C M O'Connor; R C Starling; A F Hernandez; P W Armstrong; K Dickstein; V Hasselblad; G M Heizer; M Komajda; B M Massie; J J V McMurray; M S Nieminen; C J Reist; J L Rouleau; K Swedberg; K F Adams; S D Anker; D Atar; A Battler; R Botero; N R Bohidar; J Butler; N Clausell; R Corbalán; M R Costanzo; U Dahlstrom; L I Deckelbaum; R Diaz; M E Dunlap; J A Ezekowitz; D Feldman; G M Felker; G C Fonarow; D Gennevois; S S Gottlieb; J A Hill; J E Hollander; J G Howlett; M P Hudson; R D Kociol; H Krum; A Laucevicius; W C Levy; G F Méndez; M Metra; S Mittal; B-H Oh; N L Pereira; P Ponikowski; W H W Tang; W H Wilson; S Tanomsup; J R Teerlink; F Triposkiadis; R W Troughton; A A Voors; D J Whellan; F Zannad; R M Califf
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

Review 4.  Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.

Authors:  Scott D Solomon; Adel R Rizkala; Jianjian Gong; Wenyan Wang; Inder S Anand; Junbo Ge; Carolyn S P Lam; Aldo P Maggioni; Felipe Martinez; Milton Packer; Marc A Pfeffer; Burkert Pieske; Margaret M Redfield; Jean L Rouleau; Dirk J Van Veldhuisen; Faiez Zannad; Michael R Zile; Akshay S Desai; Victor C Shi; Martin P Lefkowitz; John J V McMurray
Journal:  JACC Heart Fail       Date:  2017-06-26       Impact factor: 12.035

5.  Recognizing worsening chronic heart failure as an entity and an end point in clinical trials.

Authors:  Javed Butler; Eugene Braunwald; Mihai Gheorghiade
Journal:  JAMA       Date:  2014-08-27       Impact factor: 56.272

Review 6.  Epidemiology of heart failure with preserved ejection fraction.

Authors:  Shannon M Dunlay; Véronique L Roger; Margaret M Redfield
Journal:  Nat Rev Cardiol       Date:  2017-05-11       Impact factor: 32.419

7.  Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.

Authors:  Inder S Anand; Brian Claggett; Jiankang Liu; Amil M Shah; Thomas S Rector; Sanjiv J Shah; Akshay S Desai; Eileen O'Meara; Jerome L Fleg; Marc A Pfeffer; Bertram Pitt; Scott D Solomon
Journal:  JACC Heart Fail       Date:  2017-04       Impact factor: 12.035

Review 8.  Geographic differences in heart failure trials.

Authors:  João Pedro Ferreira; Nicolas Girerd; Patrick Rossignol; Faiez Zannad
Journal:  Eur J Heart Fail       Date:  2015-07-21       Impact factor: 15.534

9.  Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document.

Authors:  Faiez Zannad; Angeles Alonso Garcia; Stefan D Anker; Paul W Armstrong; Gonzalo Calvo; John G F Cleland; Jay N Cohn; Kenneth Dickstein; Michael J Domanski; Inger Ekman; Gerasimos S Filippatos; Mihai Gheorghiade; Adrian F Hernandez; Tiny Jaarsma; Joerg Koglin; Marvin Konstam; Stuart Kupfer; Aldo P Maggioni; Alexandre Mebazaa; Marco Metra; Christina Nowack; Burkert Pieske; Ileana L Piña; Stuart J Pocock; Piotr Ponikowski; Giuseppe Rosano; Luis M Ruilope; Frank Ruschitzka; Thomas Severin; Scott Solomon; Kenneth Stein; Norman L Stockbridge; Wendy Gattis Stough; Karl Swedberg; Luigi Tavazzi; Adriaan A Voors; Scott M Wasserman; Holger Woehrle; Andrew Zalewski; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2013-06-19       Impact factor: 15.534

Review 10.  Clinical trials have gone global: is this a good thing?

Authors:  Trudie Lang; Sisira Siribaddana
Journal:  PLoS Med       Date:  2012-06-12       Impact factor: 11.069

View more
  2 in total

Review 1.  Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial.

Authors:  Stephen J Greene; Eric J Velazquez; Kevin J Anstrom; Eric L Eisenstein; Shelly Sapp; Shelby Morgan; Tina Harding; Vandana Sachdev; Fassil Ketema; Dong-Yun Kim; Patrice Desvigne-Nickens; Bertram Pitt; Robert J Mentz
Journal:  JACC Heart Fail       Date:  2021-03-10       Impact factor: 12.035

2.  Does asymmetry in patient recruitment in large critical care trials follow the Pareto principle?

Authors:  Mahesh Ramanan; Laurent Billot; Dorrilyn Rajbhandari; John Myburgh; Simon Finfer; Rinaldo Bellomo; Balasubramanian Venkatesh
Journal:  Trials       Date:  2020-05-05       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.